The given chart illustrates the proportion of drug revenue of an unspecified company in three distinctive continents from 2002 to 2006.
Overall, the drug sales in three continents were relatively similar, with a clear decrease in the percentage of America. By contrast, the portion of drug sales in Asia increased throughout the period.
Starting with the percentage of America’s drug sales, it began at 41%, accounting for the peak in 2002. In the subsequent years, the proportion of pharmatical sales revenue in America witnessed a remarkable drop, reaching the lowest point in 2004 at 27% prior to rebounding to 30% over the next two years. For Europe, the proportion of drug revenue remained comparatively stable, with a fluctuation range from 30% to 38%, with a minium of 30% in the end of perid and maxium of 38% in 2004.
Turning to the remaining continent, in 2002, the drug income constitued the lowest, at 25%. Over the upcoming years, it experienced a considerable increase, with 30%, 35%, and 37% in 2003, 2004 and 2005 respectively. In the rest of period, the portion of drug sales reached the peak, at 40%, around doubled compared to the past 4 years